Solid-phase peptide synthesis succeeds or fails on the coupling step. This article compares the main condensation agent classes, carbodiimides, benzotriazole and oxime additives, uronium salts, phosgene derivatives, and mixed anhydrides, explains the carboxyl activation chemistry behind each, and…
The condensation agents used in solid-phase peptide synthesis fall into five working groups: carbodiimides DCC, DIC, EDCI ; benzotriazole and oxime additives plus in situ activating reagents HOBt, BOP, PyBOP, PyAOP, PyBrOP, BOP-Cl, and Oxyma Pure ; uronium salts TBTU, with EEDQ as a related carboxyl activator ; phosgene derivatives chlorophosgene and triphosgene ; and mixed anhydrides . Every one of them does the same chemical job. They activate the carboxyl group of the incoming amino acid so that the amine of the growing, resin-bound chain can attack it and close an amide bond. Choosing among them reduces to four questions: how completely the carboxyl is activated, how few side reactions the activated species generates, whether the reagent and its by-products tolerate the resin and solvent, and whether everything stays dissolved long enough to react.
Solid-phase peptide synthesis builds a chain while it is anchored to an insoluble resin. The C-terminal amino acid is loaded first, and every subsequent residue is added in a cycle of deprotection, washing, and coupling. The full sequence runs: loading, washing, deprotection, washing, coupling, repetition of that cycle for each residue, final deprotection, washing, and cleavage from the resin. Each elongation cycle is only two chemical events, deprotection and condensation, and of the two, the condensation is by far the harder. Efficient activation of the carboxyl group is the requirement, and it has to be met in a heterogeneous mixture where one reaction partner is tethered to a solid support.
Two structural facts govern reagent choice before any reagent is picked. Amino acid side chains are frequently reactive, so they must be carried through the synthesis in protected form to prevent branching and other by-products. And those protecting groups must be removable on schedule without disturbing the rest of the molecule. That is what orthogonal protection provides: protecting groups that can be removed under different conditions, so one can come off while the others remain intact.
An unactivated carboxylic acid will not acylate an amine at a useful rate under the conditions peptide synthesis tolerates. Activation converts the carboxyl into an electrophilic species that an amine can attack. The route differs by reagent class, but the endpoint is the same acylated intermediate that collapses into an amide.
For carbodiimides the sequence is direct. The carbodiimide attacks the carboxyl to give an O-acylisourea an acyl-urea intermediate. The amine then attacks the carbonyl carbon of that intermediate, and the peptide bond forms as the urea by-product departs. Carbodiimides are general dehydrating agents as well: they convert carboxylic acids into amides, esters, and anhydrides, which is exactly why they are useful here and exactly why they cause trouble elsewhere. They can also convert primary amides into nitriles, a dehydration side reaction that matters for residues carrying amide side chains, and the same activation chemistry can consume an unprotected acid side chain such as those of Asp and Glu. The practical rule that follows is short: every reactive side chain stays protected through the coupling.
Racemization is the second hazard. An activated amino acid can cyclize to an oxazolone, which loses the stereochemical information at the alpha carbon and can reopen as an epimerized species. The standard defense is an additive that traps the activated carboxyl as a less racemization-prone ester before the oxazolone forms. HOBt is that additive. 1 equivalent of HOBt is added to carbodiimide couplings to prevent racemization.
Carbodiimides are among the most widely used condensation agents in peptide chemistry, and they are the least expensive and the easiest to handle. Their advantages are cost, simplicity, and effectiveness under mild conditions. Their limitations all trace back to the urea they leave behind.
DCC produces dicyclohexylurea DCU , which is nearly insoluble in the solvents used for coupling. In a solid-phase reactor that precipitate is a real problem: it can coat the resin, it requires filtration, and it costs yield. DIC exists largely because of that problem, since its urea by-product is more soluble and stays out of the resin bed. EDCI is the water-tolerant member of the family. Both the reagent and its urea by-product are water-soluble, so they can be removed with water washes, which is why EDCI is used for modifying proteins in aqueous solution rather than for routine chain assembly on a resin.
Incomplete activation is a genuine failure mode. If the carboxyl is not fully activated, the coupling stalls, and the unreacted chain either gets capped or carries a deletion silently into the next cycle.
| Agent | Urea by-product | By-product solubility | Where it fits |
|---|---|---|---|
| DCC | Dicyclohexylurea DCU | Nearly insoluble, precipitates | Solution-phase work; poor fit for resin reactors |
| DIC | Diisopropylurea | More soluble than DCU | Standard choice for solid-phase coupling |
| EDCI | EDCI-urea | Water-soluble | Protein modification and aqueous coupling |
Additives and preformed reagents improve on bare carbodiimide activation by stabilizing the active ester. HOBt reacts with the carbodiimide to produce a highly reactive benzotriazolyl ester instead of leaving the O-acylisourea free to cyclize. That single change raises coupling efficiency and suppresses racemization, and it is the origin of the 1 equivalent HOBt practice.
BOP was among the first reagents to generate OBt esters in situ. It does not dehydrate the side-chain amides of Asn and Gln to nitriles, and it causes minimal racemization, which made it a workhorse for years. Its drawback is severe: BOP produces hexamethylphosphoramide HMPA as a by-product, and HMPA is a potent carcinogen. BOP should be handled with containment and its waste stream treated accordingly. PyBOP delivers comparable efficiency with a lower by-product hazard, which is why many groups default to it. PyAOP is effective for coupling N-methyl-protected amino acids, and PyBrOP is used for sterically hindered residues such as N-methyl amino acids and alpha,alpha-dialkylglycines. BOP-Cl is used to couple Fmoc-alpha,alpha-dialkyl amino acids to tritylphenyl resins.
The general advantages of this group are improved efficiency, fewer side reactions, and suppressed racemization, particularly for hindered residues. The limitations are cost and the handling, containment, and disposal burden that the more hazardous members carry.
| Challenge | Reagent | Basis |
|---|---|---|
| Routine coupling with racemization risk | HOBt, 1 equivalent, with a carbodiimide | Traps the active species as a benzotriazolyl ester |
| Asn or Gln side-chain amide dehydration | BOP or PyBOP | Does not dehydrate primary amides to nitriles |
| N-methyl-protected amino acids | PyAOP | Effective for this substrate class |
| Sterically hindered N-methyl and alpha,alpha-dialkylglycines | PyBrOP | Built for hindered couplings |
| Fmoc-alpha,alpha-dialkyl amino acids on tritylphenyl resin | BOP-Cl | Reported use for this resin and substrate |
| Avoiding HMPA by-product | PyBOP instead of BOP | Comparable efficiency, lower by-product hazard |
Uronium salts such as TBTU, with EEDQ as a related activator, work by forming a reactive phosphonium or uronium species. The resulting electrophile is highly reactive, which produces fast and efficient peptide bond formation, makes the class useful for sequences that are hard to dissolve or hard to couple, and tends to generate fewer side products. The trade-offs are price and control. These reagents are expensive, and careless handling can contaminate the product. Resin compatibility can also constrain where they are used.
Phosgene derivatives, chlorophosgene and triphosgene, are potent activating agents. They react with the carboxyl group to form an acylated intermediate that then reacts with the amine of the next residue. They are highly efficient, work with challenging amino acids, give high yields, and minimize racemization and side reactions. The obvious problem is toxicity. Phosgene is hazardous, the derivatives are hazardous to handle, and working with them requires specialized equipment and adds expense. Efficiency does not change the fact that many laboratories should not have them on the bench at all.
Mixed anhydrides form when an amino acid reacts with an acid chloride or another acylating agent. The anhydride is reactive enough that the amine of the next residue attacks it directly to form the peptide bond. Mixed anhydride couplings are effective, especially when combined with HOBt or pyridine, and they are versatile across a broad range of amino acids. Their weakness is control. The same reactivity that makes them fast can drive side reactions when conditions drift, and preparing the anhydride cleanly adds complexity. Anyone using them should treat the reaction conditions as the experiment, not the reagent.
Reagent selection never happens in isolation from the protecting group strategy, and the two dominant schemes are Boc/Bzl and Fmoc/tBu .
Boc/Bzl pairs an acid-labile Boc group on the alpha-amine with benzyl-based side-chain protection. It is often described as orthogonal, but it is not truly orthogonal, because both groups are acid-sensitive. What makes it work is a wide difference in acid strength. Boc is removed under mild acid, 50% TFA in DCM. Benzyl groups survive that treatment and require strong acid, HF or TFMSA, for final removal. The scheme remains widely used precisely because that gap is wide enough to exploit, even though the selectivity is one of degree rather than of mechanism.
Fmoc/tBu separates the two events by chemistry instead of by acid strength: Fmoc comes off under basic conditions, and tBu side-chain protection comes off in acid. That separation is what most modern solid-phase work uses.
The consequence for condensation agents is that the reagent, its by-products, and its waste stream all have to coexist with the deprotection chemistry happening in the same cycle. A reagent that generates a strong acid or a persistent electrophile at every coupling can erode side-chain protection across dozens of cycles. A reagent whose by-product precipitates can foul the resin before the chain is finished. Solubility matters for the same reason: reagents or peptide fragments that fall out of solution stop reacting, and the resulting deletions become visible only after cleavage and analysis.
The criteria reduce to four, and they should be checked in order. Activation efficiency: will the reagent fully activate the carboxyl for this specific residue, including hindered and N-methylated ones. Side reaction profile: does the activated species racemize, dehydrate, or attack side chains. Resin and solvent compatibility: do the reagent and its by-products survive the swelling solvent and the deprotection chemistry. Solubility: does everything, reagent included, stay dissolved.
Defaults that follow from those criteria:
The literature retrieved for this topic contains no head-to-head comparison of condensation agents, and that should be said plainly. What it does contain is evidence about what condensation chemistry is used for, and about where the field is heading.
A 2022 report in Chemical Science describes an economical route to peptides that avoids classical condensation agents altogether, using solvent-free, metal-free regioselective C-N bond cleavage of lactams PMID 35733900 . The method produced peptides in up to 99% yield without racemization or polymerization, and the authors also demonstrated segment coupling to a spider-silk repeat hexapeptide. Two conclusions follow. Racemization control is the benchmark against which any coupling chemistry is judged, and it is achievable outside the carbodiimide toolbox. And the push toward more efficient, less wasteful coupling is an active area of primary research rather than a settled question.
A 2021 review in the Journal of Peptide Science catalogs synthetic strategies for sulfonopeptides, including condensation and coupling steps alongside sulfinylation, alkylation, and sulfite displacement PMID 33913204 . The relevance is that the condensation chemistry discussed here is not restricted to natural backbones; it is part of the toolkit for building non-natural peptide mimics of interest as enzyme-inhibitor candidates.
A 2022 study in Medicinal Chemistry reports ten dipeptide-sulfonamide derivatives synthesized and screened as antimalarial and antitrypanosomal agents PMID 34097595 . In preclinical in vivo testing, one compound at 100 mg/kg inhibited Plasmodium berghei by 79.89%, comparable to artemether-lumefantrine at 79.77%. The best antitrypanosomal derivatives were less potent than diminazene aceturate, and no apparent blood, liver, or kidney toxicity was observed. This is early preclinical work on a small series of ten compounds, not a clinical result, and the antimalarial figure comes from a comparison with a single control rather than a full efficacy program. It is cited here because it shows the downstream purpose of the chemistry: small, well-defined peptides and peptide-like molecules reaching in vivo testing.
None of these three sources evaluates DIC against TBTU, or HOBt against Oxyma, and no registered clinical trial addresses reagent selection. Guidance on which condensation agent to use rests on reaction chemistry and accumulated laboratory practice, not on controlled comparative studies. That is a real limit on how strongly any recommendation can be made.
Several questions remain genuinely open.
The comparative case for Oxyma Pure is the clearest example. It is an oxime-based additive discussed in the same role as HOBt, and it has drawn interest as an alternative, but the retrieval for this article did not turn up the controlled comparisons that would establish where it wins, where it loses, and at what cost. Claims about it should be treated as provisional rather than settled.
Broader reagent comparison is similarly incomplete. There is no consolidated, controlled dataset comparing the major classes on efficiency, side reaction rate, and cost per coupling under matched conditions. Selection is therefore probabilistic: the criteria above predict which reagent is likely to work, and the synthesis itself delivers the verdict.
Scale-up exposes problems that small-scale work conceals. By-product accumulation, resin fouling, waste handling for hazardous reagents such as HMPA and phosgene derivatives, solvent volumes, and the cost of expensive uronium salts all grow faster than the batch size does. Published best practices for scaling these specific reagents are thin, and most scale-up knowledge sits inside process groups rather than in the literature.
Finally, the search for greener, more efficient activators is active but unresolved. Any new reagent has to match established ones on racemization control, the benchmark set by work such as PMID 35733900, before a switch is justified. Until that comparison exists in the literature, the four selection criteria remain the most reliable tool available, and a pilot coupling on a small scale remains the most reliable test.
Related reading: How Enzymes Build Oligopeptides and Peptide Antibiotics, Peptide Antigen Design: Key Parameters and Practical Guidelines, Enzymatic Synthesis of Oligopeptides: Five Enzyme Families, Reversible Double Linkers Reduce Amyloid Peptide Aggregation.